Who Paid My Doc Search
Menu
Organisation paid for research Program year 2022 Source: CMS Open Payments

Valley View Hospital

Neither a doctor nor a teaching hospital

Research payments

$106,091

11 payments

Through program year 2022, Valley View Hospital is reported as receiving $106,091 in research payments, across 11 payments.

By program year

4 rows
Year Kind Amount Payments
2022 Research $280 1
2021 Research $1,000 1
2020 Research $6,727 2
2019 Research $98,084 7

Breakdown

Who paid Research payments · program years 2019–2022
  1. Novartis Pharmaceuticals Corporation $89,096 2 payments
  2. Celgene Corporation $14,356 5 payments
  3. Incyte Corporation $2,639 4 payments
Studies the money was for Research payments · program years 2019–2022
  1. An Open Label Multicenter Phase Iiib Study of Ribociclib Lee011 in Combination With Letrozole for the Treatment of Postmenopausal Women With Hormone Receptor Positive HR Her2 Negative Her2 Advanced Breast Cancer Abc Who Received No Prior Hormonal Therapy $89,096 2 payments
  2. A Phase 3B Randomized Study of Lenalidomide (CC-5013) Plus Rituximab Maintenance Therapy Followed by Lenalidomide Single-Agent Maintenance Versus Rituximab in Subjects with Relapsed/Refractory Follicular, Marginal Zone, or Mantle Cell Lymphoma(CA078-P10) (CC-5013-NHL-008) $7,349 2 payments
  3. A Phase 3B Randomized Study of Lenalidomide (CC-5013) Plus Rituximab Maintenance Therapy Followed by Lenalidomide Single-Agent Maintenance Versus Rituximab in Subjects with Relapsed/Refractory Follicular, Marginal Zone, or Mantle Cell Lymphoma(CA078-P10) $5,727 1 payment
  4. A Phase 2, Open Label, Single Agent, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects With Metastatic or Surgically Unresectable Urothelial Carcinoma Harboring FGFFGFR Alterations $1,639 3 payments
  5. A Phase 3B Randomized Study of Lenalidomide (CC-50 $1,280 2 payments
  6. A Phase 2, Open Label, 2 Cohort Study of INCB050465, a PI3Kd Inhibitor, in Subjects With Relapsed or Refractory Marginal Zone Lymphoma With or Without Prior Exposure to a BTK Inhibitor, CITADEL 204 $1,000 1 payment

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2022

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record